Cargando…
S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells
BACKGROUND & OBJECTIVES: Insulin resistance associated with hyperinsulinaemia and overexpression of insulin receptors (IRs) have been intricately linked to the pathogenesis and treatment outcomes of the breast carcinoma. Studies have revealed that upregulated expression of IRs in breast cancer p...
Autores principales: | Sharma, Prateek, Kumar, Sanjeev |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118145/ https://www.ncbi.nlm.nih.gov/pubmed/30168485 http://dx.doi.org/10.4103/ijmr.IJMR_403_17 |
Ejemplares similares
-
Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups
por: Björner, Sofie, et al.
Publicado: (2016) -
Inhibition of Cancer Cell Proliferation and Metastasis by Insulin Receptor Downregulation
por: Zhang, Hua, et al.
Publicado: (2010) -
Altered Expression of Insulin Receptor Isoforms in Breast Cancer
por: Huang, Jiaqi, et al.
Publicado: (2011) -
Insulin, insulin-like growth factor–1, insulin receptor, and insulin-like growth factor–1 receptor expression in the chick eye and their regulation with imposed myopic or hyperopic defocus
por: Penha, Alexandra Marcha, et al.
Publicado: (2011) -
Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells
por: Byron, S A, et al.
Publicado: (2006)